ArticleRomanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
Mast cells - key players of digestive tumors associated angiogenesis.
Article in Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMast cells (MCs) are immune cells derived from hematopoietic cluster of differentiation (CD)34+ and CD117+ precursors that complete their maturation in peripheral tissues such as the connective and mucosal layers, perivascular and perineural regions, and secondary lymphoid organs, where they play essential roles in regulating immune responses. The MC's dual role as both an effector and regulator of angiogenesis makes it a valuable indicator of tumor aggressiveness and a potential therapeutic target in digestive malignancies. MATERIALS AND
methods41 cases of digestive tumors with gastric, pancreatic and colorectal origins and their corresponding liver metastasis were evaluated by morphological and immunohistochemical techniques. The effects of Sodium Cromoglycate (Cromolyn) applied to a xenograft of cells derived from a liver metastasis of colorectal origin with a desmoplastic histological growth pattern, applied to chorioallantoic membrane (CAM) were analyzed. CD34 and mast cell tryptase (MCT) were used as primary antibodies.
resultsA statistically significant correlation was noticed between mast cell density (MCD) outside the metastasis area and microvascular density (MVD) in the metastasis area with pancreatic origin (p=0.023). A statistically significant correlation was noted with a p-value of 0.046 for the desmoplastic histological growth pattern, between MCD in the metastatic area and the degree of differentiation. After therapy with Cromolyn, increased MVD and the absence of positive MCT were noticed in the xenograft.
conclusionsThe analysis of MCD demonstrated marked variability depending on tumor type, differentiation, and histological growth pattern. Targeting MC activation could represent an adjuvant of anti-angiogenic therapy in metastatic digestive cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.